tiprankstipranks
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
US Market
LYEL
Lyell Immunopharma
RESEARCH TOOLSreports
Want to see LYEL full AI Analyst Report?

Lyell Immunopharma (LYEL) Stock News & Sentiment

159 Followers
Lyell Immunopharma: Differentiated Cell Therapy Platform and Strong Leadership Underpin Buy Rating
Premium
Ratings
Lyell Immunopharma: Differentiated Cell Therapy Platform and Strong Leadership Underpin Buy Rating
18d ago
LYEL
Morning News Wrap-Up 4/10/26: Today’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up 4/10/26: Today’s Biggest Stock Market Stories!
22d ago
MU
AMD
Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst
Premium
Market News
Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst
23d ago
LYEL
Lyell Immunopharma: Undervalued CAR-T Innovator With Strong Ronde-cel Profile, Hidden LYL273 Upside, and Cash Runway to 2027 Supporting Buy Rating and $44 Target
Premium
Ratings
Lyell Immunopharma: Undervalued CAR-T Innovator With Strong Ronde-cel Profile, Hidden LYL273 Upside, and Cash Runway to 2027 Supporting Buy Rating and $44 Target
23d ago
LYEL
Lyell Immunopharma: Differentiated Dual‑Target CAR‑T Pipeline and Upcoming Clinical Milestones Support Buy Rating and Acquisition Potential
Premium
Ratings
Lyell Immunopharma: Differentiated Dual‑Target CAR‑T Pipeline and Upcoming Clinical Milestones Support Buy Rating and Acquisition Potential
1M ago
LYEL
LYEL Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
LYEL Earnings this Week: How Will it Perform?
2M ago
LYEL
Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know
Premium
Company Announcements
Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know
2M ago
LYEL
More LYEL News >

LYEL News on the Web

Lyell Immunopharma: Differentiated Cell Therapy Platform and Strong Leadership Underpin Buy Rating
TipRanks News
Bullish
Morning News Wrap-Up 4/10/26: Today’s Biggest Stock Market Stories!
TipRanks News
Bearish
Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst
TipRanks News
Neutral
Lyell Immunopharma: Undervalued CAR-T Innovator With Strong Ronde-cel Profile, Hidden LYL273 Upside, and Cash Runway to 2027 Supporting Buy Rating and $44 Target
TipRanks News
Bullish
Lyell Immunopharma initiated with a Buy at Needham
TipRanks News
Bullish
Lyell Immunopharma: Differentiated Dual‑Target CAR‑T Pipeline and Upcoming Clinical Milestones Support Buy Rating and Acquisition Potential
TipRanks News
Bullish
Lyell Immunopharma price target raised to $39 from $32 at Lucid Capital
TipRanks News
Bullish
Major Investors Double Down on Lyell Immunopharma in Bold New Move
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
LYEL
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.25 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is LYEL’s Media Buzz Sentiment?
1 articles about LYEL were published this week. In an average week, 1.25 articles are published.
    What is LYEL’s weekly average amount of articles?
    In an average week, 1.25 articles about LYEL are published.
      What is LYEL’s News Sentiment?
      100% of articles about LYEL were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week